Cargando…

Artesunate for the treatment of severe malaria: A retrospective review of patients admitted to two tertiary hospital intensive care units in Johannesburg, South Africa

BACKGROUND: Globally, malaria is one of the six major causes of deaths from communicable diseases. In South Africa, malaria is known to be endemic in three provinces. Two large trials, AQUAMAT and SEAQUAMAT, demonstrated the superiority of intravenous (IV) artesunate compared to quinine. A systemati...

Descripción completa

Detalles Bibliográficos
Autores principales: Tadzimirwa, Ratidzo, Omar, Shahed, Brown, Jacqueline M., Kalla, Ismail S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AOSIS OpenJournals 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378158/
https://www.ncbi.nlm.nih.gov/pubmed/34485479
http://dx.doi.org/10.4102/sajid.v35i1.174
_version_ 1783740784279814144
author Tadzimirwa, Ratidzo
Omar, Shahed
Brown, Jacqueline M.
Kalla, Ismail S.
author_facet Tadzimirwa, Ratidzo
Omar, Shahed
Brown, Jacqueline M.
Kalla, Ismail S.
author_sort Tadzimirwa, Ratidzo
collection PubMed
description BACKGROUND: Globally, malaria is one of the six major causes of deaths from communicable diseases. In South Africa, malaria is known to be endemic in three provinces. Two large trials, AQUAMAT and SEAQUAMAT, demonstrated the superiority of intravenous (IV) artesunate compared to quinine. A systematic review (including the above trials) demonstrated a mortality benefit for adult patients treated with artesunate, but included studies that were conducted in Asia with no adult data available for Africa. Given the lack of local data, we conducted this study to investigate the use of artesunate for the treatment of severe malaria at two academic adult intensive care units (ICUs) in Johannesburg. METHODS: We undertook a retrospective patient record review. All patients admitted to the two ICUs and treated for severe malaria using artesunate were included. The study period extended from April 2010 to April 2014. The primary outcome was to determine the observed mortality and relate it to the predicted mortality based on the Acute Physiology and Chronic Health Evaluation (APACHE II) severity of illness score. The ratio of the observed mortality to the expected mortality based on the APACHE II severity of illness score provides a standardised mortality ratio (SMR). Clinical and laboratory parameters data were analysed. RESULTS: There were 56 patients included in the study, of which 40 were male (71.4%). The mean APACHE II score was 19 (standard deviation 5.4). We observed a lower than predicted mortality rate of 21.4% (SMR 0.66). Human immunodeficiency virus (HIV) was the most prevalent comorbidity (32%). There was no travel history in 26.8% of patients. Heart rate, respiratory rate and Glasgow Coma Scale (GCS) all improved significantly from admission to the time of discharge (p ≤ 0.01). Acidaemia, bilirubin, urea and bleeding risk (platelet count) also improved (p ≤ 0.01). Mechanical ventilation was associated with an increased risk of death (OR 35; CI 7.0–182). CONCLUSION: In this retrospective two-centre study, IV artesunate was associated with a lower than predicted mortality in adult patients with severe malaria requiring ICU admission.
format Online
Article
Text
id pubmed-8378158
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AOSIS OpenJournals
record_format MEDLINE/PubMed
spelling pubmed-83781582021-09-03 Artesunate for the treatment of severe malaria: A retrospective review of patients admitted to two tertiary hospital intensive care units in Johannesburg, South Africa Tadzimirwa, Ratidzo Omar, Shahed Brown, Jacqueline M. Kalla, Ismail S. S Afr J Infect Dis Original Research BACKGROUND: Globally, malaria is one of the six major causes of deaths from communicable diseases. In South Africa, malaria is known to be endemic in three provinces. Two large trials, AQUAMAT and SEAQUAMAT, demonstrated the superiority of intravenous (IV) artesunate compared to quinine. A systematic review (including the above trials) demonstrated a mortality benefit for adult patients treated with artesunate, but included studies that were conducted in Asia with no adult data available for Africa. Given the lack of local data, we conducted this study to investigate the use of artesunate for the treatment of severe malaria at two academic adult intensive care units (ICUs) in Johannesburg. METHODS: We undertook a retrospective patient record review. All patients admitted to the two ICUs and treated for severe malaria using artesunate were included. The study period extended from April 2010 to April 2014. The primary outcome was to determine the observed mortality and relate it to the predicted mortality based on the Acute Physiology and Chronic Health Evaluation (APACHE II) severity of illness score. The ratio of the observed mortality to the expected mortality based on the APACHE II severity of illness score provides a standardised mortality ratio (SMR). Clinical and laboratory parameters data were analysed. RESULTS: There were 56 patients included in the study, of which 40 were male (71.4%). The mean APACHE II score was 19 (standard deviation 5.4). We observed a lower than predicted mortality rate of 21.4% (SMR 0.66). Human immunodeficiency virus (HIV) was the most prevalent comorbidity (32%). There was no travel history in 26.8% of patients. Heart rate, respiratory rate and Glasgow Coma Scale (GCS) all improved significantly from admission to the time of discharge (p ≤ 0.01). Acidaemia, bilirubin, urea and bleeding risk (platelet count) also improved (p ≤ 0.01). Mechanical ventilation was associated with an increased risk of death (OR 35; CI 7.0–182). CONCLUSION: In this retrospective two-centre study, IV artesunate was associated with a lower than predicted mortality in adult patients with severe malaria requiring ICU admission. AOSIS OpenJournals 2020-12-18 /pmc/articles/PMC8378158/ /pubmed/34485479 http://dx.doi.org/10.4102/sajid.v35i1.174 Text en © 2020. The Authors https://creativecommons.org/licenses/by/4.0/Licensee: AOSIS. This work is licensed under the Creative Commons Attribution License.
spellingShingle Original Research
Tadzimirwa, Ratidzo
Omar, Shahed
Brown, Jacqueline M.
Kalla, Ismail S.
Artesunate for the treatment of severe malaria: A retrospective review of patients admitted to two tertiary hospital intensive care units in Johannesburg, South Africa
title Artesunate for the treatment of severe malaria: A retrospective review of patients admitted to two tertiary hospital intensive care units in Johannesburg, South Africa
title_full Artesunate for the treatment of severe malaria: A retrospective review of patients admitted to two tertiary hospital intensive care units in Johannesburg, South Africa
title_fullStr Artesunate for the treatment of severe malaria: A retrospective review of patients admitted to two tertiary hospital intensive care units in Johannesburg, South Africa
title_full_unstemmed Artesunate for the treatment of severe malaria: A retrospective review of patients admitted to two tertiary hospital intensive care units in Johannesburg, South Africa
title_short Artesunate for the treatment of severe malaria: A retrospective review of patients admitted to two tertiary hospital intensive care units in Johannesburg, South Africa
title_sort artesunate for the treatment of severe malaria: a retrospective review of patients admitted to two tertiary hospital intensive care units in johannesburg, south africa
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378158/
https://www.ncbi.nlm.nih.gov/pubmed/34485479
http://dx.doi.org/10.4102/sajid.v35i1.174
work_keys_str_mv AT tadzimirwaratidzo artesunateforthetreatmentofseveremalariaaretrospectivereviewofpatientsadmittedtotwotertiaryhospitalintensivecareunitsinjohannesburgsouthafrica
AT omarshahed artesunateforthetreatmentofseveremalariaaretrospectivereviewofpatientsadmittedtotwotertiaryhospitalintensivecareunitsinjohannesburgsouthafrica
AT brownjacquelinem artesunateforthetreatmentofseveremalariaaretrospectivereviewofpatientsadmittedtotwotertiaryhospitalintensivecareunitsinjohannesburgsouthafrica
AT kallaismails artesunateforthetreatmentofseveremalariaaretrospectivereviewofpatientsadmittedtotwotertiaryhospitalintensivecareunitsinjohannesburgsouthafrica